Eagle Pharmaceuticals, Inc. (EGRX) - חוב להון עצמי

The price trend shown below illustrates the debt-to-equity ratio of Eagle Pharmaceuticals (EGRX), which stands at 0.00. The business relies on the production of optimized generics of well-known medications, which minimizes development costs. Renewing patents for legacy compounds allows the company to transform them into high-yield assets. Meanwhile, Eagle Pharmaceuticals (EGRX) is building a network of specialized solutions for clinics, although expansion is constrained by strict oversight regarding formula uniqueness.

Investors assess business resilience through the balance of debt and equity, where an increasing ratio signals heightened default risks. The total liabilities-to-equity ratio reflects the degree of leverage, which for Eagle Pharmaceuticals (EGRX), given its low R&D costs and high scalability, indicates efficient capital management, as clearly evidenced by the company's financial leverage history.